cas 93267-04-0|| where to buy (R)-Methyl 2-((tert-butoxycarbonyl)amino)-3-iodopropanoate

Nom du produit:(R)-Methyl 2-((tert-butoxycarbonyl)amino)-3-iodopropanoate

IUPAC Name:methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM255848-1000g	in stock	Ťĳƴ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 93267-04-0 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:93267-04-0; Formule moléculaire:C9H16INO4; Point de fusion:-; Code SMILES:O=C(OC)[C@@H](NC(OC(C)(C)C)=O)CI; Densité:

: Numéro de catalogue:CM255848; Poids moléculaire:329.13; Point d'ébullition:356.5°C at 760 mmHg; N° Mdl:MFCD00216579; Stockage:Keep in dark place, store at 2-8°C.

: Amino Acids and Peptides; Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.; amino acids wholesale; if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!

: Selatogrel; Selatogrel is an investigational, potent, fast-acting, reversible, and highly selective P2Y12 inhibitor, being developed for the treatment of an acute myocardial infarction (AMI) in patients with a recent history of AMI. It is intended to be self-administered subcutaneously via a drug delivery system (autoinjector).
This novel, self-administered emergency agent has the potential to protect heart muscle in the very early phase of an AMI – in the crucial time between symptom onset and first medical attention – so as to treat the ongoing AMI and prevent early death.

: Zetomipzomib; Kezar Life Sciences announces clinical hold of Zetomipzomib IND for treatment of lupus nephritis(LN). Zetomipzomib (KZR-616) is a selective inhibitor of the immunoproteasome currently undergoing clinical investigation in autoimmune disorders.
LN is a disease comprising a spectrum of vascular, glomerular and tubulointerstitial lesions and develops in approximately 50% of SLE patients within 10 years of their initial diagnosis. LN is associated with considerable morbidity, including an increased risk of end-stage renal disease requiring dialysis or renal transplantation and an increased risk of death. There are limited approved therapies for the treatment of LN. Management typically consists of induction therapy to achieve remission and long-term maintenance therapy to prevent relapse.